Prognosis

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
Venerdì, Maggio 3, 2024
Cell, National Cancer Institute, Macrophage, Sapienza University of Rome, Genome, Glucose, Wistar Institute, Gene, Brain, Tumor microenvironment, Wistar, Metabolomics, Neuroscience, Immunity, Ben, Medical research, Microglia, Research, Proteomics, Immunology, Histone, Malignancy, Gene expression, Neoplasm, Aurelia, Cancer, Collaborative writing, DSM-IV codes, Prognosis, Immunosuppression, Immunotherapy, Duke School, Disease, GLUT1, Patient, Metabolism, Immune system, Angelica, Vaccine

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

MiRNA Sequencing and Assay Market Research 2024: Robust Growth with Emerging Trends in Personalized Medicine and Advancements in Sequencing Technologies - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Maggio 3, 2024
Biotechnology, Genetics, Health, Cancer, Genomics, Prognosis, Cardiology, RNA, Traction, Research, NGS, Disease, Patient, Neurology, Data analysis, Gene expression, Diagnosis, Messenger, Biomarker, Molecular biology, Immunity, Risk assessment, Drug discovery, Medicine, Algorithm, Medical imaging

One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.

Key Points: 
  • One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.
  • This has led to a surge in the adoption of miRNA sequencing and assay technologies in both research and clinical settings.
  • The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market.
  • The rising interest in personalized medicine has emerged as a powerful catalyst in boosting the Global MiRNA Sequencing and Assay Market.

Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

Retrieved on: 
Mercoledì, Maggio 1, 2024
Cytogenetics, Hospital, Prognosis, Research, International, American Cancer Society, MD, Digital, Pathology, Transport, Growth, Quest Diagnostics, Intelligence, Marie Cassidy, Diagnosis, Senior, Patient, Microbiology, Acquisition, Workforce, DGX, Medical imaging

SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

Key Points: 
  • Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.
  • At closing, PathAI Diagnostics' state-of-the-art digitized laboratory in Memphis, Tennessee will become Quest's AI and digital R&D and solutions center, supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics.
  • Under separate agreements, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the United States.
  • "The PathAI Diagnostics laboratory in Memphis will allow Quest to accelerate its digital journey with an already digitized laboratory."

CREATV BIO PRESENTS CANCER SCREENING AND CANCER DIAGNOSTICS DATA AT 1ST INTERNATIONAL CONFERENCE ON POLYPLOID GIANT CANCER CELLS

Retrieved on: 
Martedì, Aprile 30, 2024
Giant, Cancer, Prognosis, Lung cancer, Monroe Dunaway Anderson, Conference, PD-L1, University, Patient, Biology, MD Anderson Cancer Center, Hypertrophy, Biomarker, Medical imaging

HOUSTON, April 30, 2024 /PRNewswire/ -- Creatv Bio, A Division of Creatv MicroTech, Inc. (Creatv), ( https://creatvbio.com/ ) and collaborators were invited to present clinical data from Creatv's blood test for cancer screening and diagnostics at the 1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications – held February 16 and 17 at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Key Points: 
  • HOUSTON, April 30, 2024 /PRNewswire/ -- Creatv Bio, A Division of Creatv MicroTech, Inc. (Creatv), ( https://creatvbio.com/ ) and collaborators were invited to present clinical data from Creatv's blood test for cancer screening and diagnostics at the 1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications – held February 16 and 17 at The University of Texas MD Anderson Cancer Center in Houston, Texas.
  • This conference brought together for the first-time international researchers and clinicians to discuss the biology and clinical applications of Polyploid Giant Cancer Cells (PGCCs) and the role they may play in cancer.
  • The Conference featured 28 presentations on PGCCs and more than a dozen posters.
  • "These results are quite encouraging and give clinicians another tool to help guide their treatment of cancer patients."

New Report Reveals Myriad Problems with Big Cats in Captivity, Calls for a Phase-Out of Breeding and Keeping Big Cats at Zoos

Retrieved on: 
Martedì, Aprile 30, 2024
Mortality, Born Free, Prognosis, Health, Animal, Breeding, Lion, Cat, Infant, Life, Tiger, Breed, Human, Injury, BPSA, Inbreeding, Overcrowding, Infection, Hunting

Using case studies and independent analysis of zoo databases, the report provides a comprehensive overview of the exploitation of big cats in zoos across North America.

Key Points: 
  • Using case studies and independent analysis of zoo databases, the report provides a comprehensive overview of the exploitation of big cats in zoos across North America.
  • Although zoos claim to "protect" big cats, many animals have died from captivity-related causes such as infection, injuries from enclosure companions, and high infant mortality.
  • Due to inbreeding and habituation to humans, big cats kept in zoos are generally not candidates for release to the wild.
  • Keeping big cats in zoos clearly serves no positive end, except for those who want to pay to see them.

Caris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data Offering

Retrieved on: 
Martedì, Aprile 30, 2024
Sequence, Cancer, AUC, WTS, AI, Prognosis, RNA, MD, Partnership, Doctor of Philosophy, Research, DNA, Health information management, Data, Patient, Record, RWD, Health, WES, Biomarker, Medicine, Quality of life, COTA, Medical imaging

IRVING, Texas and NEW YORK, April 30, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and COTA, Inc. (COTA), an oncology real-world data (RWD) and analytics company used by the world's leading pharmaceutical companies, today announced a collaboration to expand their multi-modal data offerings to support and accelerate biopharmaceutical drug development and patient care. 

Key Points: 
  • The combination of the breadth and depth of Caris' genomic, transcriptomic, proteomic and imaging data and COTA's high-quality curated clinical data that captures the treatment journeys and outcomes of cancer patients will result in a broad real-world, multi-modal data offering, at scale, to power the next wave of cancer therapeutics.
  • "Caris' partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development.
  • Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing (WES) DNA coverage and Whole Transcriptome Sequencing (WTS) RNA coverage for every viable sample.
  • "By combining COTA's high-quality, curated data sourced from electronic health records with Caris' molecular data, life sciences researchers will be able to capture previously unseen insights to optimize cancer treatments that can improve a patient's prognosis and quality of life," said C.K.

Kura Oncology Reports First Quarter 2024 Financial Results

Retrieved on: 
Giovedì, Maggio 2, 2024
FDA, Cancer, KURA, Investment, Venetoclax, HNSCC, Food, Prognosis, Research, Renal cell carcinoma, FTI, AML, Webcast, Disease, LDAC, Patient, Azacitidine, QT interval, BTD, Acute myeloid leukemia, FLT3, Head, Initiate, ID, Breakthrough therapy, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2024 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2024 were $36.3 million, compared to $25.2 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $18.2 million, compared to $11.4 million for the first quarter of 2023.
  • ET / 1:30 p.m. PT today, May 2, 2024, to discuss the financial results for the first quarter 2024 and to provide a corporate update.

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Retrieved on: 
Martedì, Aprile 23, 2024
Pain, FDA, Brain, Cancer, Food, Prognosis, Survival, Breast, Research, FABP5, Transport, Dicarboxylic acid, IND, Drug discovery, Patient, Metabolism, Neuropathic pain, FABP, FABP7, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry

Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.

Key Points: 
  • Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.
  • Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
  • In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN).
  • For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Retrieved on: 
Lunedì, Aprile 22, 2024
MSN, Safety, Protein-bound paclitaxel, OTCQB, Prognosis, Survival, Oxaliplatin, Doctor of Philosophy, Therapy, Patient, Fluorouracil, Dicarboxylic acid, Data analysis, PBLA, Pharmaceutical industry

MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.

Key Points: 
  • MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
  • As of the latest assessment, less than half of the required events for the interim analysis have occurred.
  • "The early indications from the ASPIRE trial support this belief, and we remain committed to advancing this important study and look forward to sharing the interim results in March 2025."
  • Panbela will continue to monitor the progress of the ASPIRE trial and provide updates as appropriate.

XORTX Announces Publication of Key Research in ADPKD

Retrieved on: 
Lunedì, Aprile 22, 2024
Kidney disease, University, Xanthine oxidase, Mouse, Kidney, Uric acid, XO, Prognosis, American Journal, Cyst, Research, Oxipurinol, SUA, Disease, Patient, Serum, Polycystic kidney disease, Therapy, PKD, Pharmaceutical industry

This study shows, for the first time, that chronically increased SUA can significantly increase cyst index and increase kidney size in ADPKD.

Key Points: 
  • This study shows, for the first time, that chronically increased SUA can significantly increase cyst index and increase kidney size in ADPKD.
  • Dr. Allen Davidoff, CEO of XORTX, stated, “We are pleased to have supported this pioneering research in polycystic kidney disease by Dr. Charles Edelstein of the University of Colorado.
  • In human ADPKD, kidney size and declining kidney filtering capacity are correlated and are key indicators of disease progression and prognosis.
  • These mechanistic studies are important for the planning of future clinical studies of xanthine oxidase inhibition in patients with ADPKD.”